Literature DB >> 1681064

Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity.

T Sakane1, M Akizuki, M Yoshida, S Yamashita, T Nadai, M Hashida, H Sezaki.   

Abstract

The aim of the present study has been to confirm the existence of a transport pathway for a drug (cephalexin) to the cerebrospinal fluid (CSF) directly from the nasal cavity, by comparing the drug's concentrations in CSF after intranasal (i.n.), intravenous (i.v.) and intraduodenal (i.d.) administration. Higher levels of the drug were found in CSF following i.n. administration compared with the i.v. and i.d. routes, even though its plasma concentrations were similar. These findings suggest the existence of a direct transport pathway for cephalexin from the nasal cavity to the CSF. The concentration of drug in CSF at 15 min after i.n. administration was higher than that at 30 min. In contrast, its concentrations in CSF at 15 min after i.v. and i.d. administration were not significantly different from those at 30 min. The results confirm the presence of a direct transport pathway to CSF from the nasal cavity. This pathway may represent a new delivery route to CSF and possibly to brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681064     DOI: 10.1111/j.2042-7158.1991.tb03510.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  17 in total

1.  Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.

Authors:  H D Kao; A Traboulsi; S Itoh; L Dittert; A Hussain
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups.

Authors:  Damon Klebe; Jerry J Flores; Devin W McBride; Paul R Krafft; William B Rolland; Tim Lekic; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-20       Impact factor: 6.200

3.  Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy.

Authors:  Ratnesh Jain; Swapna Nabar; Prajakta Dandekar; Vandana Patravale
Journal:  Pharm Res       Date:  2010-02-12       Impact factor: 4.200

4.  Biovector nanoparticles improve antinociceptive efficacy of nasal morphine.

Authors:  D Betbeder; S Spérandio; J P Latapie; J de Nadai; A Etienne; J M Zajac; B Francés
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

5.  Nipecotic acid: systemic availability and brain delivery after nasal administration of nipecotic acid and n-butyl nipecotate to rats.

Authors:  Hongna Wang; Anwar A Hussain; Peter J Wedlund
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae.

Authors:  Karunya K Kandimalla; Maureen D Donovan
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

7.  Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs.

Authors:  Abeer M Al-Ghananeem; Ashraf A Traboulsi; Lewis W Dittert; Anwar A Hussain
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

8.  Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.

Authors:  Prashanth Manda; Avadhesh Singh Kushwaha; Santanu Kundu; H N Shivakumar; Seong Bong Jo; S Narasimha Murthy
Journal:  J Control Release       Date:  2015-12-28       Impact factor: 9.776

9.  Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study.

Authors:  Mascha P van den Berg; Paul Merkus; Stefan G Romeijn; J Coos Verhoef; Frans W H M Merkus
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

10.  In situ and in vivo study of nasal absorption of paeonol in rats.

Authors:  Xiaolan Chen; Yang Lu; Shouying Du; Bing Xu; Shan Wang; Yongsong Zhai; Xiao Song; Pengyue Li
Journal:  Int J Mol Sci       Date:  2010-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.